The Oncologic Drugs Advisory Committee Votes of April 2021-Implications for the Fate of Accelerated Approval

JAMA Oncol. 2021 Nov 1;7(11):1607-1609. doi: 10.1001/jamaoncol.2021.3046.

Authors

Kerrington Powell¹, Mark P Lythgoe², Vinay Prasad³

Affiliations

¹ College of Medicine, Texas A&M Health Science Center, College Station, Texas.
² Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, United Kingdom.
³ University of California, San Francisco, San Francisco.

PMID: 34236432
DOI: 10.1001/jamaoncol.2021.3046

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Advisory Committees*
Drug Approval*
Humans
Medical Oncology
Politics
United States
United States Food and Drug Administration